Novel Ways for Immune Intervention in Immunotherapy: Mucosal Allergy Vaccines

Immunology and Allergy Clinics of North America

Volumn 26, Issue 2, 2006, Pages 283-306

  Mascarell, Laurent ^a   Van Overtvelt, Laurence ^a   Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALLERGEN; ALUMINUM HYDROXIDE; ANTIGEN; BACTERIAL TOXIN; BEE VENOM; CALCIUM PHOSPHATE; COLECALCIFEROL; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DIPEPTIDE; GLUCOCORTICOID; HEMAGGLUTININ; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; ISCOM; LIPOSOME; OUTER MEMBRANE PROTEIN A; PHOSPHORYL LIPID A; POLLEN EXTRACT; RC 529; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VACCINE; VENOM; VEROTOXIN; VIROSOME;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANTIGEN SPECIFICITY; ASTHMA; AUTOIMMUNE DISEASE; BINDING AFFINITY; BORDETELLA PERTUSSIS; CELL BASED GENE THERAPY; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DESENSITIZATION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EXPRESSION VECTOR; GENE VECTOR; HONEYBEE; HUMAN; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; ISOTOPE LABELING; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LANGERHANS CELL; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MOUTH MUCOSA; MUCOSA; MUCOSAL IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PARIETARIA; PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; REVIEW; RHINOCONJUNCTIVITIS; RISK FACTOR; ROTAVIRUS; SENDAI VIRUS; SUBCUTANEOUS TISSUE; SWELLING; T LYMPHOCYTE; UPPER RESPIRATORY TRACT; VACCINE PRODUCTION; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS PARTICLE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; MUCOUS MEMBRANE; VACCINES;

EID: 33646391232     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.02.009     Document Type: Review

References (152)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 2 (1911) 1572-1573
2. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 2 (1911) 814-817
3. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 (1998) 558-562
4. Larche M. Specific immunotherapy. Br Med Bull 56 (2000) 1019-1036
5. Gehlhar K., Schlaak M., Becker W., et al. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 29 (1999) 497-506
6. Michils A., Mairesse M., Ledent C., et al. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol 102 (1998) 118-126
7. Pichler C.E., Helbling A., and Pichler W.J. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56 (2001) 301-306
8. Moller C., Dreborg S., Ferdousi H.A., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109 (2002) 251-256
9. Mowat A.M., Parker L.A., Beacock-Sharp H., et al. Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci 1029 (2004) 1-8
10. Mayer L., and Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 4 (2004) 407-419
11. Faria A.M., and Weiner H.L. Oral tolerance. Immunol Rev 206 (2005) 232-259
12. Akdis C.A., and Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 55 (2000) 522-530
13. Durham S.R., and Till S.J. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102 (1998) 157-164
14. Till S.J., Francis J.N., Nouri-Aria K., et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 113 (2004) 1025-1034 [quiz 35]
15. Ebner C. Systemic immune response to specific immunotherapy. Clin Exp Allergy 28 (1998) 781-783
16. Garcia N.M., Lynch N.R., Di Prisco M.C., et al. Nonspecific changes in immunotherapy with house dust extract. J Investig Allergol Clin Immunol 5 (1995) 18-24
17. Wachholz P.A., and Durham S.R. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 33 (2003) 1171-1174
18. Iliopoulos O., Proud D., Adkinson Jr. N.F., et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 87 (1991) 855-866
19. Durham S.R., Ying S., Varney V.A., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4 + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97 (1996) 1356-1365
20. van Neerven R.J., Wikborg T., Lund G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163 (1999) 2944-2952
21. van Neerven R.J., Arvidsson M., Ipsen H., et al. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 34 (2004) 420-428
22. Pierson-Mullany L.K., Jackola D., Blumenthal M., et al. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 84 (2000) 241-243
23. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
24. Niederberger V., Horak F., Vrtala S., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14677-14682
25. Hakansson L., Heinrich C., Rak S., et al. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 99 (1997) 551-562
26. Durham S.R., Varney V.A., Gaga M., et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 29 (1999) 1490-1496
27. Monteseirin J., Bonilla I., Camacho J., et al. Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. J Allergy Clin Immunol 107 (2001) 623-626
28. Wilson D.R., Irani A.M., Walker S.M., et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 31 (2001) 1705-1713
29. Furin M.J., Norman P.S., Creticos P.S., et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 88 (1991) 27-32
30. Wilson D.R., Nouri-Aria K.T., Walker S.M., et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 107 (2001) 971-976
31. Robinson D.S., Larche M., and Durham S.R. Tregs and allergic disease. J Clin Invest 114 (2004) 1389-1397
32. El Biaze M., Boniface S., Koscher V., et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58 (2003) 844-853
33. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy 28 (1998) 917-920
34. Hamid Q.A., Schotman E., Jacobson M.R., et al. Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99 (1997) 254-260
35. Benjaponpitak S., Oro A., Maguire P., et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 103 (1999) 468-475
36. Ebner C., Siemann U., Bohle B., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 27 (1997) 1007-1015
37. Secrist H., Chelen C.J., Wen Y., et al. Allergen immunotherapy decreases interleukin 4 production in CD4 + T cells from allergic individuals. J Exp Med 178 (1993) 2123-2130
38. Medicines CoSo. Desensitising vaccines: an allergist's view. BMJ 293 (1986) 1169-1170
39. Canonica G.W., and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 (2003) 437-448 [quiz 49]
40. Deuschl H., and Johansson G.O. Hyposensitization of patients with allergic rhinitis by intranasal administration of chemically modified grass pollen allergen. A pilot study. Acta Allergol 32 (1977) 248-262
41. Nickelsen J.A., Goldstein S., Mueller U., et al. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. J Allergy Clin Immunol 68 (1981) 33-40
42. Georgitis J.W., Reisman R.E., Clayton W.F., et al. Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 71 (1983) 71-76
43. Andri L., Senna G.E., Betteli C., et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 47 (1992) 318-323
44. Andri L., Senna G., Betteli C., et al. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 91 (1993) 987-996
45. D'Amato G., Lobefalo G., Liccardi G., et al. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 25 (1995) 141-148
46. Andri L., and Senna G. Local nasal immunotherapy. Allergy 50 (1995) 190
47. Andri L., Senna G., Betteli C., et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol 97 (1996) 34-41
48. Passalacqua G., Albano M., Riccio A.M., et al. Local nasal immunotherapy: experimental evidences and general considerations. Allergy 52 (1997) 10-16
49. Nickelsen J.A., Georgitis J.W., Mueller U.R., et al. Local nasal immunotherapy for ragweed-allergic rhinitis. III. A second year of treatment. Clin Allergy 13 (1983) 509-519
50. Nickelsen J.A., Goldstein S., Mueller U., et al. Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. J Allergy Clin Immunol 68 (1981) 41-45
51. Tsitoura D.C., DeKruyff R.H., Lamb J.R., et al. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4 + T cells. J Immunol 163 (1999) 2592-2600
52. Winkler B., Bolwig C., Seppala U., et al. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 110 (2003) 376-385
53. Bagnasco M., Mariani G., Passalacqua G., et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 100 (1997) 122-129
54. Passalacqua G., Altrinetti V., Mariani G., et al. Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin Exp Allergy 35 (2005) 880-883
55. Rebien W., Puttonen E., Maasch H.J., et al. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatr 138 (1982) 341-344
56. Taudorf E., and Weeke B. Orally administered grass pollen. Allergy 38 (1983) 561-564
57. Cooper P.J., Darbyshire J., Nunn A.J., et al. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 14 (1984) 541-550
58. Mosbech H., Dreborg S., Madsen F., et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 42 (1987) 451-455
59. Urbanek R., Burgelin K.H., Kahle S., et al. Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur J Pediatr 149 (1990) 545-550
60. Moller C., Dreborg S., Lanner A., et al. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 41 (1986) 271-279
61. Taudorf E., Laursen L.C., Lanner A., et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 80 (1987) 153-161
62. Taudorf E., Laursen L., Lanner A., et al. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 83 (1989) 589-594
63. Giovane A.L., Bardare M., Passalacqua G., et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 24 (1994) 53-59
64. Leng X., Fu Y.X., Ye S.T., et al. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann Allergy 64 (1990) 27-31
65. Litwin A., Flanagan M., Entis G., et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 100 (1997) 30-38
66. Sollid L.M. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2 (2002) 647-655
67. MacPherson G., Milling S., Yrlid U., et al. Uptake of antigens from the intestine by dendritic cells. Ann N Y Acad Sci 1029 (2004) 75-82
68. Bousquet J., Scheinmann P., Guinnepain M.T., et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54 (1999) 249-260
69. La Rosa M., Ranno C., Andre C., et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 104 (1999) 425-432
70. Wilson D.R., Torres L.I., and Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2 (2003) CD002893
71. Clavel R., Bousquet J., and Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53 (1998) 493-498
72. Vourdas D., Syrigou E., Potamianou P., et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53 (1998) 662-672
73. Bousquet J., Van Cauwenberge P., and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 (2001) S147-S334
74. Pajno G.B., Morabito L., Barberio G., et al. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55 (2000) 842-849
75. Marogna M., Spadolini I., Massolo A., et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 115 (2005) 1184-1188
76. Smith H., White P., Annila I., et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 114 (2004) 831-837
77. Baena-Cagnani C.E., Passalacqua G., Baena-Cagnani R.C., et al. Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr Opin Allergy Clin Immunol 5 (2005) 173-177
78. Khinchi M.S., Poulsen L.K., Carat F., et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
79. Moingeon P., Batard T., Fadel R., et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 (2006) 151-165
80. Garcia B.E., Sanz M.L., Gato J.J., et al. IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol 3 (1993) 26-33
81. Mothes N., Heinzkill M., Drachenberg K.J., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33 (2003) 1198-1208
82. Marcucci F., Sensi L., Frati F., et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 56 (2001) 1091-1095
83. Passalacqua G., Albano M., Fregonese L., et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351 (1998) 629-632
84. Marcucci F., Sensi L., Frati F., et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 58 (2003) 657-662
85. Silvestri M., Spallarossa D., Battistini E., et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol 12 (2002) 52-59
86. Passalacqua G., Albano M., Riccio A., et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 104 (1999) 964-968
87. Rolinck-Werninghaus C., Kopp M., et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 136 (2005) 134-141
88. Lima M.T., Wilson D., Pitkin L., et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 32 (2002) 507-514
89. Ippoliti F., De Santis W., Volterrani A., et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 14 (2003) 216-221
90. Fenoglio D., Puppo F., Cirillo I., et al. Sublingual specific immunotherapy reduces PBMC proliferations. Allerg Immunol (Paris) 37 (2005) 147-151
91. Ciprandi G., Fenoglio D., Cirillo I., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 95 (2005) 38-44
92. Bagnasco M., Passalacqua G., Villa G., et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 31 (2001) 54-60
93. Allam J.P., Novak N., Fuchs C., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 112 (2003) 141-148
94. Novak N., Bieber T., and Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 167 (2001) 797-804
95. von Bubnoff D., Bezold G., Matz H., et al. Quantification of indoleamine 2,3-dioxygenase gene induction in atopic and non-atopic monocytes after ligation of the high-affinity receptor for IgE, Fc(epsilon)RI and interferon-gamma stimulation. Clin Exp Immunol 132 (2003) 247-253
96. van Wilsem E.J., Breve J., Savelkoul H., et al. Oral tolerance is determined at the level of draining lymph nodes. Immunobiology 194 (1995) 403-414
97. van Helvoort J.M., Samsom J.N., Chantry D., et al. Preferential expression of IgG2b in nose draining cervical lymph nodes and its putative role in mucosal tolerance induction. Allergy 59 (2004) 1211-1218
98. Drachenberg K.J., Wheeler A.W., Stuebner P., et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 (2001) 498-505
99. Drachenberg K.J., Heinzkill M., Urban E., et al. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 31 (2003) 270-277
100. Repa A., Grangette C., Daniel C., et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22 (2003) 87-95
101. Grangette C., Muller-Alouf H., Goudercourt D., et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 69 (2001) 1547-1553
102. Grangette C., Nutten S., Palumbo E., et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 102 (2005) 10321-10326
103. Chapat L., Chemin K., Dubois B., et al. Lactobacillus casei reduces CD8 + T cell-mediated skin inflammation. Eur J Immunol 34 (2004) 2520-2528
104. Zuany-Amorim C., Manlius C., Trifilieff A., et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 169 (2002) 1492-1499
105. Arkwright P.D., and David T.J. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol 149 (2003) 1029-1034
106. Pizza M., Giuliani M.M., Fontana M.R., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 (2001) 2534-2541
107. Bradney C.P., Sempowski G.D., Liao H.X., et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 76 (2002) 517-524
108. Staats H.F., Bradney C.P., Gwinn W.M., et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol 167 (2001) 5386-5394
109. Sanders M.T., Brown L.E., Deliyannis G., et al. ISCOM-based vaccines: the second decade. Immunol Cell Biol 83 (2005) 119-128
110. Hobson P., Barnfield C., Barnes A., et al. Mucosal immunization with DNA vaccines. Methods 31 (2003) 217-224
111. Klavinskis L.S., Barnfield C., Gao L., et al. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162 (1999) 254-262
112. Boisgerault F., Moron G., and Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1 (2002) 101-109
113. Niikura M., Takamura S., Kim G., et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293 (2002) 273-280
114. El Azami El Idrissi M., Ladant D., et al. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40 (2002) 1661-1665
115. Jeannin P., Renno T., Goetsch L., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 1 (2000) 502-509
116. Haicheur N., Benchetrit F., Amessou M., et al. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 15 (2003) 1161-1171
117. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 69 (2001) 6434-6444
118. Muller U., Akdis C.A., Fricker M., et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101 (1998) 747-754
119. Verhoef A., Alexander C., Kay A.B., et al. T cell epitope immunotherapy induces a CD4 + T cell population with regulatory activity. PLoS Med 2 (2005) e78
120. Larche M., and Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11 (2005) S69-S76
121. Jakobsen C.G., Bodtger U., Poulsen L.K., et al. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin Exp Allergy 35 (2005) 193-198
122. Jutel M., Jaeger L., Suck R., et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
123. Gafvelin G., Thunberg S., Kronqvist M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138 (2005) 59-66
124. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10 + CD4 + CD25 + T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 (2003) 1255-1261
125. Nasser S.M., Ying S., Meng Q., et al. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 31 (2001) 3704-3713
126. Gardner L.M., Thien F.C., Douglass J.A., et al. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4 + CD25 + interleukin-10 + T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 34 (2004) 1209-1219
127. Bjorksten B., Moller C., Broberger U., et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 41 (1986) 290-295
128. Passalacqua G., Villa G., Altrinetti V., et al. Sublingual swallow or spit?. Allergy 56 (2001) 578
129. Bahceciler N.N., Arikan C., Taylor A., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 136 (2005) 287-294
130. Haan L., Verweij W.R., Holtrop M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19 (2001) 2898-2907
131. Hagiwar Y., Tsuji T., Iwasaki T., et al. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine 19 (2001) 2071-2079
132. Pajak B., Garze V., Davies G., et al. The adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo. Vaccine 21 (2003) 836-842
133. Baldridge J.R., Yorgensen Y., Ward J.R., et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18 (2000) 2416-2425
134. Mason K.W., Zhu D., Scheuer C.A., et al. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine 22 (2004) 3449-3456
135. Gallichan W.S., Woolstencroft R.N., Guarasci T., et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166 (2001) 3451-3457
136. Santeliz J.V., Van Nest G., Traquina P., et al. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 109 (2002) 455-462
137. Fukushima A., Yoo Y.C., Yoshimatsu K., et al. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine 14 (1996) 485-491
138. Boussiotis V.A., Tsai E.Y., Yunis E.J., et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 105 (2000) 1317-1325
139. McGuirk P., McCann C., and Mills K.H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195 (2002) 221-231
140. Bracci L., Canini I., Puzelli S., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 (2005) 2994-3004
141. Kutzler M.A., Robinson T.M., Chattergoon M.A., et al. Communization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175 (2005) 112-123
142. van Overvelt L., and Moingeon P. T cell adjuvants and novel strategies for their identification. In: Schjins V., and O'Hagan D. (Eds). Immunopotentiators in Modern Vaccines (2005), Academic Press, Surrey (UK)
143. Durrer P., Gluck U., Spyr C., et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21 (2003) 4328-4334
144. Felnerova D., Viret J.F., Gluck R., et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 (2004) 518-529
145. de Jonge M.I., Hamstra H.J., Jiskoot W., et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 22 (2004) 4021-4028
146. Hu K.F., Lovgren-Bengtsson K., and Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 51 (2001) 149-159
147. Waeckerle-Men Y., and Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57 (2005) 475-482
148. Ball J.M., Hardy M.E., Atmar R.L., et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 72 (1998) 1345-1353
149. Ball J.M., Graham D.Y., Opekun A.R., et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117 (1999) 40-48
150. Takamura S., Niikura M., Li T.C., et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 11 (2004) 628-635
151. Shi W., Liu J., Huang Y., et al. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75 (2001) 10139-10148
152. Bonifaz L.C., Bonnyay D.P., Charalambous A., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199 (2004) 815-824